Compare AZZ & BLLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AZZ | BLLN |
|---|---|---|
| Founded | 1956 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Medical Specialities |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3B | 3.9B |
| IPO Year | N/A | 2025 |
| Metric | AZZ | BLLN |
|---|---|---|
| Price | $125.34 | $80.90 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 6 |
| Target Price | $116.33 | ★ $137.83 |
| AVG Volume (30 Days) | 152.8K | ★ 243.2K |
| Earning Date | 01-07-2026 | 12-09-2025 |
| Dividend Yield | ★ 0.65% | N/A |
| EPS Growth | ★ 730.47 | N/A |
| EPS | ★ 10.65 | N/A |
| Revenue | ★ $1,616,858,000.00 | $254,136,000.00 |
| Revenue This Year | $5.09 | $98.01 |
| Revenue Next Year | $5.31 | $35.84 |
| P/E Ratio | $11.57 | ★ N/A |
| Revenue Growth | 1.53 | ★ 254.30 |
| 52 Week Low | $70.90 | $80.00 |
| 52 Week High | $127.88 | $138.70 |
| Indicator | AZZ | BLLN |
|---|---|---|
| Relative Strength Index (RSI) | 67.86 | 40.13 |
| Support Level | $121.26 | $80.00 |
| Resistance Level | $127.88 | $94.16 |
| Average True Range (ATR) | 2.68 | 6.92 |
| MACD | -0.10 | -0.38 |
| Stochastic Oscillator | 75.27 | 4.50 |
AZZ Inc is a provider of galvanizing and a variety of metal coating solutions and coil coating solutions to a broad range of end markets in North America. The company's operating segment consists of Metal Coatings, Precoat Metals, and Infrastructure Solutions. The company generates the majority of its revenue from the Precoat Metals segment, which provides coil coating application of protective and decorative coatings and related value-added downstream processing for steel and aluminum coils. Geographically, the company generates the majority of its revenue from the United States.
BillionToOne Inc is a precision diagnostics company revolutionizing molecular testing with its patented Quantitative Counting Templates (QCT) platform. This technology enables ultrasensitive, single-molecule DNA quantification, making genetic testing more accurate, affordable, and accessible. The company serves prenatal screening and oncology markets with non-invasive tests that detect fetal genetic risks and monitor cancer therapy response.